Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies February 12, 2019 What to Know About Getting Access to New Cancer Advances Presented... September 14, 2022 For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and... March 31, 2022 Load more HOT NEWS FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma 10 Things About You That Change When You Lose Your Parents Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy The Mediterranean Diet
